Dr. Andrew A. Jackson, MD
Hematology & Oncology (Hematology & Oncology Physician)
9180 Pinecroft Dr Ste 600
Shenandoah, TX 77380
Who else practices at this address →
Montgomery County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at Houston (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 531
Licensed in Texas since 2014, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: University of Texas Medical School at Houston
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license Q0464 (first issued 2014; active) -
Internal Medicine Physician
TX license Q0464 (first issued 2014; active) -
Medical Oncology Physician
TX license Q0464 (first issued 2014; active) -
Student in an Organized Health Care Education/Training Program
TX license BP1-0040195
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Hermann Hospital System Houston, TX
- Houston Methodist the Woodlands Hospital The Woodlands, TX
- Houston Methodist Willowbrook Hospital Houston, TX
- Memorial Hermann Northeast Hospital Humble, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 531
- Services billed
- 194,395
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 43,350 | 49 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 21,600 | 15 |
| Injection, paclitaxel, 1 mg | 12,906 | 14 |
| Injection, fosaprepitant, 1 mg | 9,150 | 27 |
| Injection, pembrolizumab, 1 mg | 7,000 | 15 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,272 | 45 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 998 | 271 |
| Established patient office or other outpatient visit, 30-39 minutes | 684 | 256 |
| Injection, palonosetron hcl, 25 mcg | 680 | 32 |
| Blood test, comprehensive group of blood chemicals | 438 | 95 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Shenandoah, TX | 119 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Shenandoah, TX | 95 |
| Prednisone Other prescribers in Shenandoah, TX | 88 |
| Gabapentin Other prescribers in Shenandoah, TX | 63 |
| Folic Acid Other prescribers in Shenandoah, TX | 61 |
| Dexamethasone Other prescribers in Shenandoah, TX | 57 |
| Potassium Chloride Other prescribers in Shenandoah, TX | 53 |
| Acyclovir Other prescribers in Shenandoah, TX | 41 |
| Duloxetine Hcl Other prescribers in Shenandoah, TX | 39 |
| Levothyroxine Sodium Other prescribers in Shenandoah, TX | 36 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 18 payments worth $13,187 in total to this clinician.
| Alexion Pharmaceuticals, Inc. | $12,026 |
|---|---|
| Lilly USA, LLC | $938 |
| Tempus Ai, Inc | $98.87 |
| Pharmacosmos Therapeutics Inc. | $48.23 |
| Pharmaessentia USA Corporation | $16.86 |
| Janssen Pharmaceuticals, Inc | $15.99 |
| Eisai Inc. | $15.66 |
| Amneal Pharmaceuticals LLC | $14.12 |
| Consulting Fee | $11,978 |
|---|---|
| Travel and Lodging | $836 |
| Food and Beverage | $358 |
| Education | $15.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. Mar 20, 2025 | Consulting Fee | $5,520 |
| Alexion Pharmaceuticals, Inc. Nov 13, 2025 | Consulting Fee | $2,300 |
| Alexion Pharmaceuticals, Inc. Jul 24, 2025 | Consulting Fee | $1,610 |
| Alexion Pharmaceuticals, Inc. Jun 12, 2025 | Consulting Fee | $1,610 |
| Lilly USA, LLC Nov 14, 2025 | Consulting Fee JAYPIRCA · Oncology | $938 |
| Alexion Pharmaceuticals, Inc. Feb 27, 2025 | Travel and Lodging travel to Fort Worth, TX · in-kind Company’s descriptionConsulting Expenses | $366 |
| Alexion Pharmaceuticals, Inc. Feb 27, 2025 | Travel and Lodging travel to Dallas, TX · in-kind Company’s descriptionConsulting Expenses | $345 |
| Alexion Pharmaceuticals, Inc. Feb 28, 2025 | Travel and Lodging travel to Dallas, TX · in-kind Company’s descriptionConsulting Expenses | $125 |
| Janssen Pharmaceuticals, Inc Sep 2, 2025 | Education in-kind | $15.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $93,838 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo Inc. · Recruiting · NCT06330064 - Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia
Janssen Research & Development, LLC - A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia i…
Novartis Pharmaceuticals Corporation - A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL
Genentech, Inc. - A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Eli Lilly and Company · Recruiting · NCT06721013
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.